Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc. (“Carmot”), a privately owned US company based in Berkeley, California.

Oxford Nanopore Technologies PLC (LSE:ONT) has secured a £70 million investment from French in-vitro diagnostics (IVD) company bioMérieux, in exchange for a 3.5% stake.

On July 19, 2023, the Third People’s Hospital of Shenzhen (hereinafter referred to as Shenzhen Third Hospital) and Shenzhen New Industries Biomedical Engineering Co., Ltd. (hereinafter referred to as Snibe) successfully held an exchange seminar and a signing ceremony of strategic cooperation on “Industry-University-Research-Hospital-Application”.

Siemens Healthineers said Thursday that it has received US Food and Drug Administration clearance for an analyzer designed for immunoassay and clinical chemistry testing in low- to medium-volume laboratories.

Roche said Tuesday that it secured US Food and Drug Administration 510(k) clearances for a pair of assays to aid diagnosis of Alzheimer's disease measuring levels of beta-amyloid and tau proteins.

Oxford Nanopore Technologies (Oxford Nanopore) and leading China-based diagnostic companies, Zheijiang Digena Diagnostic Technology Co. Ltd (Digena) and Wuhan Dgensee Clinical Laboratory Co., Ltd (Dgensee), today announced a series of strategic collaborations that aim to bring nanopore sequencing technology and instruments to the clinical market in China.

T2 Biosystems said on Friday that it is collaborating with Vanderbilt University Medical Center to implement and evaluate the firm's T2Bacteria Panel in clinical settings.

The major controlling party of Leadman, signed a cooperation agreement with GoBroad Health Group to build a research hospital project in Guangzhou Sino-Singapore Knowledge City.

Merck and Prometheus Biosciences, Inc. announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion.

Agilent Technologies Inc. announced a strategic partnership with PathAI, a leading provider of AI-powered research tools and services for pathology, to deliver biopharmaceutical organizations a solution that combines Agilent’s assay development expertise and PathAI’s algorithm development capabilities.